But is there differentiation among the three MEK inhibitors? Shouldn't one be their best shot at this target?
Only two of the three are ARRY MEKs. The GSK MEK is strictly GSKs and not in some partnership with ARRY. (Conway was just giving some props to the competition and I guess a bit of a slight to Bayer/RDEA, among others, who are also working on MEKs.)
Selumetinib, the ARRY MEK partnered with AZN, has been partnered for several years (believe that was an 04 deal or so). MEK162, partnered with NVS, is a much more recent deal. ARRY has said before that MEK162 is much more potent than selumetinib. But, they have also said before at least in one instance that potency isn't necessarily an issue with MEKs (implying selumetinib is plenty potent enough). Perhaps MEK162 may have better PK and other properties as well (selumetinib was actually originally a mix and drink formulation before it was developed into a pill). In any event, the two MEKs are being taken down entirely different paths as AZN is developing selumetinib in combo with chemo whereas NVS is developing MEK162 in combo with other targeted agents (PI3K, mTOR, etc.).
Market Data 
Markets 
AI
